Topic:

M&A

Latest Headlines

Latest Headlines

Medical device, diagnostic venture investment at $2.7B, highest since 2008

Med tech venture investing may lag biotech by more than half, but it's coming on strong. As venture-backed exits pick up, a real devotion to breakthrough innovation seems to be whetting investor appetites. A total of $2.7 billion was invested by VCs last year in medical devices and diagnostics, with $748 million of that total coming during the fourth quarter.

Roche bets $545M on Trophos' once-failed orphan drug

Roche has signed a deal to trade up to €470 million ($545 million) for Trophos, a company at work on a mid-stage treatment for the rare and debilitating spinal muscular atrophy.

With Rytary approval in the bag, Impax Labs scouts buyouts in CNS, generics

Sounds like Impax Laboratories' October pickup of Lineage Therapeutics and Tower Holdings was just the beginning of an M&A streak. The company is "aggressively hunting" further buyouts and is in ongoing talks with multiple targets, its CEO says.

The 2015 biotech takeover target list includes some hot new players

With the big multinationals like Merck, Roche, Pfizer and J&J joining some of the most aggressive biotechs (think Shire) in roaming the planet in search of the right biotech targets to acquire, you can expect to see a steady stream of fresh speculation among analysts over which companies figure as the most likely buyout--and the next place to score some quick cash by investors.

Tobira eyes Wall Street with Regado merger, targeting NASH

Tobira Therapeutics, moving on from a failed IPO of its own, is plotting a merger with the struggling Regado Biosciences, a deal that would get it on the public market as it develops a treatment for liver disease.

Shire's deal for NPS hasn't curbed its M&A appetite

Shire's M&A wheelhouse is still churning after its $5.2 billion buyout of NPS Pharmaceuticals. CEO Flemming Ornskov told Bloomberg that the Dublin-based company's recent acquisition won't prevent it from making more deals in the future--especially where rare disease drugs are concerned.

Is once-skeptical J&J coming around on pharma's breakup craze?

SAN FRANCISCO-- Johnson & Johnson has been pretty quiet over the past couple of years as it's watched its Big Pharma peers slim down like there's no tomorrow. But now, it seems the pharma giant may be coming around to the idea--or so CEO Alex Gorsky said Monday at the JP Morgan Healthcare Conference.

Roche bets $1.2B on Foundation Medicine with deal for majority stake

Roche is throwing the full weight of its global rep and more than $1 billion behind Foundation Medicine's ambitious sequencing technology, designed to tailor cancer treatment to particular patients and guide development of new cancer drugs.

While pharma feasts on M&A, Teva has yet to pick up a fork

Since taking the helm at Teva early last year, CEO Erez Vigodman has expressed interest in bolstering several areas, including emerging markets, biosimilars and complex generics. But so far, he hasn't inked any deals to help his company do it, and judging where his competitors now stand after a feverish year of pharma M&A, it's high time to change that, analysts say.

AmerisourceBergen storms into animal health with $2.5B purchase of MWI

Rapidly expanding drug wholesaler AmerisourceBergen said Monday it plans to acquire MWI Veterinary Supply for $2.5 billion, or $190 a share--a rich 8% premium over its closing price Friday and 17% higher than MWI's average closing price over the last three months. The companies expect to close the deal during the March quarter.